Work

Reply

Year: 2016
Type: letter
Abstract: Potential conflict of interest: Dr. Roberts advises for and received grants from Wako. He consults for Axis and Medscape. He advisesfor Bayer. He received grants from Ariad, BTG, and Gilead. REPLY: We thank Altaii et al. for their interest in our article “Aspirin use and the risk of cholangiocarcinoma.”1 They used a large clinical registry for external validation of the main findings of our article, which also showed an association between aspirin use and a lower risk of cholangiocarcinoma (CCA). This result provides additional supporting evidence for the potential role of aspirin for chemoprevention of CCA. However, the result should be interpreted with caution. Large databases, such as the clinical registry the authors used, may have provided a robust validation of the association between aspirin and the risk of CCA; however, as pointed out by Bagante et al.,2 these analyses may still suffer from a lack of detailed information on the dose and duration of aspirin use, as well as from confounding due to concomitant administration of nonsteroidal anti‐inflammatory drugs, which were already described as limitations of our article. Although our study used several sensitivity analyses to overcome this limitation, this issue may still be pertinent to the work of Altaii et al. In 2015, the U.S. Preventive Services Task Force recommended aspirin as the first pharmacological agent for chemoprevention of cancer in a population not characterized as high risk. Recently, Cao et al. reported on the population‐wide impact of aspirin use and the risk for cancer, showing a lower overall risk for cancer (relative risk [RR], 0.97), more particularly, gastrointestinal tract cancer (RR, 0.85), in regular aspirin users.3 Although Cao et al.'s study did not investigate CCA separately, this study provides accumulating evidence for the role of aspirin in preventing cancers, particularly cancers such as CCA which have strong associations with inflammatory conditions, such as primary sclerosing cholangitis (PSC) and biliary stone disease. Ideally, additional confirmatory evidence from a prospective, randomized trial of aspirin use for chemoprevention of CCA would provide the most robust evidence. However, as we mentioned in our article, because of the relatively low incidence of CCA, a prospective, randomized control might not be feasible for practical reasons, such as the longer follow‐up period needed, and the large number of participants needed to detect a sufficiently large effect size to demonstrate a clinically meaningful chemopreventive effect of aspirin for CCA. Nevertheless, it may be possible to perform a prospective, randomized trial in individuals who are at high risk of developing CCA, for example, those with PSC. Furthermore, recent advances in cancer genetics, genomics, and biomarkers raise the possibility that the use of aspirin for cancer prevention may be personalizable to the specific individuals most likely to benefit from the use of aspirin chemoprevention.
Source: Hepatology
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2547828878
Cites: 3
Cited by:
Related to: 10